background
angiotensin
convert
enzym
monocarboxylas
degrad
angiotensin
ii
angiotensin
also
function
receptor
sever
acut
respiratori
syndrom
sar
coronaviru
sarscov
highli
express
lung
heart
patient
sar
also
suffer
cardiac
diseas
includ
arrhythmia
sudden
cardiac
death
systol
diastol
dysfunct
studi
mice
infect
human
strain
sarscov
encephalomyocard
viru
examin
mrna
protein
express
autopsi
heart
sampl
patient
succumb
sar
crisi
toronto
canada
use
investig
impact
sar
myocardi
structur
inflamm
protein
express
result
pulmonari
infect
human
sarscov
mice
led
myocardi
infect
mark
decreas
express
confirm
critic
role
mediat
sarscov
infect
heart
sarscov
viral
rna
detect
autopsi
human
heart
sampl
obtain
patient
succumb
sar
crisi
toronto
sar
outbreak
macrophagespecif
stain
show
mark
increas
macrophag
infiltr
evid
myocardi
damag
patient
sarscov
heart
presenc
sarscov
heart
also
associ
mark
reduct
protein
express
conclus
data
show
sarscov
mediat
myocardi
inflamm
damag
associ
downregul
myocardi
system
may
respons
myocardi
dysfunct
advers
cardiac
outcom
patient
sar
human
rodent
angiotensin
convert
enzym
endotheliumbound
carboxymonopeptidas
singl
activesit
catalyt
region
whose
express
limit
mainli
endotheli
cell
arteri
arteriol
venul
variou
organ
includ
heart
lung
kidney
loss
lead
agedepend
cardiomyopathi
kidney
diseas
also
enhanc
pulmonari
cardiac
renal
injuri
addit
peptidas
action
also
function
receptor
sever
acut
respiratori
syndrom
coronaviru
sarscov
express
necessari
pulmonari
infect
sarscov
sever
acut
respiratori
syndrom
sar
spread
rapidli
world
lead
signific
morbid
acut
often
lethal
lung
failur
mortal
approxim
despit
modernday
therapi
toronto
sar
outbreak
associ
loss
live
consider
burden
healthcar
system
huge
econom
impact
fatal
sar
associ
viraem
respons
suggest
sarscov
may
affect
organ
interestingli
patient
infect
sarscov
suffer
cardiac
diseas
includ
systol
diastol
dysfunct
arrhythmia
sudden
death
hypothes
interact
sarscov
heart
could
contribut
sarsmedi
myocardi
inflamm
damag
show
pulmonari
infect
sarscov
mice
lead
myocardi
sarscov
manner
coupl
downregul
myocardi
mrna
loss
protein
patient
die
sar
presenc
sarscov
heart
associ
greater
macrophag
infiltr
myocardi
damag
associ
decreas
myocardi
protein
express
result
demonstr
play
key
role
mediat
sarscov
infect
heart
combin
downregul
myocardi
could
underli
pathophysiolog
mechan
sarsassoci
heart
diseas
mutant
mice
previous
describ
male
litterm
mutant
wildtyp
control
use
studi
experi
perform
accord
institut
guidelin
sarscov
beij
strain
isol
use
infect
mice
via
intranas
rout
day
mice
kill
heart
remov
analys
wildtyp
mice
age
week
maintain
steril
pathogenfre
environ
inject
periton
plaqueform
unit
encephalomyocard
emc
viru
normal
salin
previous
describ
mice
kill
day
postinfect
heart
asept
remov
frozen
liquid
nitrogen
anim
experi
perform
accord
institut
guidelin
canadian
council
anim
care
greater
toronto
area
ontario
canada
patient
die
sar
patient
underw
autopsi
dr
j
butani
staff
cardiovascular
pathologist
univers
health
network
offici
pathologist
sar
victim
control
group
consist
autopsi
ageand
gendermatch
patient
intub
ventil
die
pneumonia
sepsi
time
period
studi
carri
accord
institut
research
ethic
board
review
trichrom
haematoxylineosin
stain
visual
carri
previous
describ
assess
architectur
alter
inflamm
fibrosi
macrophag
tlymphocyt
specif
stain
use
antibodi
respect
carri
previous
describ
paraffinembed
section
pretreat
use
pepsin
digest
method
follow
treatment
mous
monoclon
antibodi
dako
lab
clone
dilut
mississauga
canada
rabbit
polyclon
antibodi
dako
lab
dilut
section
incub
biotinyl
multilink
secondari
antibodi
id
lab
biotechnolog
inc
london
canada
treat
hors
peroxidaseconjug
strepavidin
label
reagent
id
lab
biotechnolog
inc
macrophag
count
degre
inflamm
fibrosi
cardiomyocyt
crosssect
area
obtain
three
section
heart
five
random
view
section
previous
describ
apoptosi
assess
termin
deoxynucleotidyl
transferasemedi
dntp
endlabel
tunel
use
apoptag
plu
kit
intergen
purchas
new
york
ny
usa
immunohistochemistri
carri
use
antibodi
previous
describ
quantifi
previous
describ
ethic
approv
realtim
pcr
analysi
human
heart
sampl
sarscov
perform
previous
describ
revers
transcriptas
polymerasechain
reaction
rtpcr
analysi
agreement
diagnost
criteria
sar
establish
variou
agenc
includ
world
health
organ
centr
diseas
control
cdc
homogen
heart
sampl
purifi
use
shredder
column
prior
rna
isol
use
rneasi
mini
kit
qiagen
inc
mississauga
canada
rtpcr
carri
use
real
art
hpacoronaviru
viru
lightcycl
rt
reagent
assay
artu
gmbh
hamburg
germani
lightcycl
realtim
platform
roch
diagnost
laval
canada
region
sarscov
rna
polymeras
gene
amplifi
use
previous
publish
method
western
blot
analysi
myocardi
protein
carri
use
primari
mous
polyclon
antibodi
gener
laboratori
dilut
secondari
goat
antimous
antibodi
bd
bioscienc
mississauga
canada
previous
describ
analysi
myocardi
mrna
express
carri
use
taqman
realtim
pcr
use
forward
primer
revers
primer
probe
previous
describ
use
anova
follow
student
neumankeul
test
multipl
comparison
test
student
ttest
use
comparison
two
group
angiotensin
convert
enzym
function
receptor
sarscov
mediat
sarscov
pulmonari
infect
examin
myocardi
respons
pulmonari
infect
sarscov
within
day
follow
sarscov
infect
mark
presenc
sarscov
heart
wildtyp
mice
sarscov
level
reduc
heart
mice
provid
first
evid
depend
myocardi
sarscov
infect
express
fig
interestingli
process
lead
partial
downregul
mrna
express
wildtyp
mice
fig
associ
complet
loss
myocardi
protein
level
fig
result
show
wellvalid
pulmonari
murin
model
sar
sarscov
clearli
infect
heart
modul
express
deciph
whether
effect
express
mediat
directli
sarscov
vs
secondari
myocard
process
studi
encephalomyocard
emc
virusinduc
murin
model
viral
myocard
consist
impact
sarscov
myocardi
mrna
express
emc
viral
myocard
associ
signific
decreas
mrna
fig
contrast
myocardi
protein
level
show
signific
increas
fig
g
suggest
increas
transcript
effici
mrna
reduc
proteolyt
process
result
demonstr
pulmonari
infect
sarscov
murin
model
lead
myocardi
sarscov
manner
associ
decreas
myocardi
mrna
express
specif
reduct
myocardi
protein
level
presenc
sarscov
autopsi
heart
sampl
associ
myocardi
damag
interestingli
sever
cardiac
dysfunct
also
describ
patient
sar
given
high
express
heart
coupl
observ
sarscov
detect
plasma
sar
patient
examin
whether
pulmonari
sarscov
infect
lead
myocardi
sarscov
infect
patient
die
sar
examin
archiv
postmortem
autopsi
heart
tissu
patient
succumb
sar
crisi
evid
myocardi
sarscov
infect
twenti
patient
confirm
diagnos
sar
sarscov
detect
lung
studi
revers
transcriptasepolymeras
chain
reaction
analysi
show
patient
posit
sarscov
genom
detect
heart
fig
averag
viral
load
copi
sarscov
per
gram
heart
tissu
age
year
importantli
durat
ill
significantli
shorten
patient
detect
sarscov
heart
n
day
vs
patient
without
sarscov
heart
n
day
p
fig
result
indic
patient
sar
pulmonari
sarscov
infect
clearli
lead
neg
impact
ill
durat
compar
patient
die
sar
without
sarscov
heart
sarscov
close
bar
n
p
compar
sarscov
group
bh
repres
trichromestain
myocardi
section
obtain
patient
die
nonsar
relat
sepsi
bacteri
pneumonia
b
sar
evid
sarscov
heart
c
sar
without
evid
sarscov
heart
show
increas
interstiti
fibrosi
inflamm
e
cardiomyocyt
hypertrophi
base
myocyt
crosssect
area
mcsa
f
without
evid
apoptosi
patient
die
sar
g
without
h
evid
sarscov
heart
scale
bar
repres
lm
p
compar
group
vlve
vhve
patient
die
nonsar
relat
sepsi
open
bar
vlve
vhve
patient
die
sar
sarscov
heart
grey
bar
vlve
vhve
patient
die
sar
without
sarscov
heart
close
bar
n
per
group
european
journal
clinic
investig
vol
heart
diseas
sever
acut
respiratori
syndrom
sarscov
infect
heart
result
aggress
ill
earlier
death
trichromestain
show
increas
myocardi
inflamm
interstiti
fibrosi
patient
sarscov
detect
heart
fig
presenc
myocardi
inflamm
reduc
express
respons
myocardi
sarscov
infect
associ
patholog
hypertrophi
shown
increas
cardiomyocyt
crosssect
area
fig
assess
apoptosi
use
tunel
stain
reveal
increas
apoptosi
autopsi
heart
sampl
fig
h
presenc
sarscov
heart
suggest
could
lead
myocardi
inflamm
use
posit
control
group
consist
patient
die
sar
without
evid
sarscov
heart
age
year
neg
control
group
consist
patient
die
bacteri
pneumonia
sar
n
age
year
immunohistochem
stain
postmortem
myocardi
tissu
use
macrophagespecif
cellsurfac
marker
reveal
signific
amount
macrophag
infiltr
fig
clearli
increas
patient
sarscov
heart
minor
elev
patient
without
sarscov
heart
fig
contrast
immunohistochem
stain
tcell
specif
cellsurfac
marker
show
myocardi
lymphocyt
infiltr
minim
fig
signific
differ
lymphocyt
count
group
fig
fi
repres
immunohistochemistri
illustr
repres
section
patient
die
sar
evid
sarscov
heart
f
sar
without
evid
sarscov
heart
g
posit
control
section
obtain
human
spleen
h
quantif
myocardi
lymphocyt
count
scale
bar
repres
lm
p
compar
group
vlve
vhve
patient
die
nonsar
relat
sepsi
open
bar
vlve
vhve
patient
die
sar
sarscov
heart
grey
bar
vlve
vhve
patient
die
sar
without
sarscov
heart
close
bar
n
per
group
abil
sarscov
util
receptor
vivo
presenc
sarscov
heart
suggest
sarscov
interact
myocardi
system
hypothes
presenc
sarcov
heart
could
associ
decreas
protein
express
consist
observ
murin
model
immunohistochemistri
myocardi
protein
express
show
presenc
sarscov
heart
associ
mark
downregul
protein
express
fig
quantifi
shown
fig
specif
antibodi
shown
preincub
human
recombin
mg
ml
kindli
provid
apeiron
biolog
austria
block
immunostain
nativ
protein
fig
patient
infect
sar
viru
suffer
cardiac
diseas
rang
systol
diastol
dysfunct
arrhythmia
sudden
death
studi
provid
evid
function
myocardi
sarscov
receptor
vivo
respiratori
sarscov
infect
murin
model
lead
sarscov
infect
heart
decreas
myocardi
mrna
express
cytokinemedi
transcript
downregul
mrna
could
lead
decreas
mrna
level
sarscov
emcmedi
viral
myocard
virusmedi
receptor
downmodul
describ
multipl
virus
includ
hiv
measl
pulmonari
sarscov
complet
loss
protein
heart
infect
sarscov
could
secondari
activ
tace
sar
spike
protein
known
cleav
releas
due
sarscov
bind
endotheli
cell
lead
endocytosi
ligand
receptor
complex
subsequ
intracellular
degrad
patient
succumb
sar
sarscov
detect
heart
subject
suggest
sarscov
capabl
infect
myocardium
suscept
individu
show
patient
sarscov
heart
die
consider
earlier
suggest
myocardi
sarscov
infect
associ
aggress
cours
ill
sarscov
interact
led
sarsassoci
cardiomyopathi
like
contribut
signif
icantli
morbid
mortal
patient
sar
consist
cardiac
diseas
patient
succumb
sar
previous
report
bilater
pulmonari
oedema
associ
bilater
pleural
effus
frequent
observ
time
autopsi
increas
myocardi
interstiti
fibrosi
patient
sarscov
heart
consist
recent
find
show
sarscov
nucleocapsid
n
protein
potenti
transform
growth
factorbetamedi
fibrosi
consist
observ
lung
tissu
patient
affect
sar
cd
posit
macrophag
detect
sarsposit
heart
absenc
lymphocyt
invas
contrast
classic
viral
myocard
seen
enterovirus
herpesviru
type
associ
promin
lymphocyt
infiltr
sarscovinduc
myocardi
inflamm
mediat
predominantli
macrophag
result
product
chemokin
deleteri
effect
myocardi
sarscov
infect
could
perpetu
prompt
sever
downregul
result
increas
ang
ii
action
loss
cardioprotect
effect
ang
activ
tace
sar
spike
protein
lead
increas
releas
tnfa
myocardi
dysfunct
could
also
secondari
strong
interferonmedi
immunopatholog
event
associ
immun
respons
patient
sar
cardiovascular
involv
could
explain
mark
age
depend
mortal
seen
patient
sar
decreas
cardiovascular
reserv
age
consist
key
sarscov
receptor
patient
diabet
mellitu
express
increas
show
greater
suscept
sar
result
impli
interact
infecti
agent
key
receptor
signal
pathway
cardiovascular
system
may
confer
uniqu
sensit
sarscov
potenti
viral
infect
inde
interact
subsequ
activ
signal
influenza
viru
import
determin
viral
replic
may
lead
advers
cardiovascular
effect
set
avian
influenza
epidem
